COLOMBO, NICOLETTA
COLOMBO, NICOLETTA
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
2025 Liu, J; Colombo, N; Oza, A; Frenel, J; Corr, B; Rubinstein, M; Nevadunsky, N; Lheureux, S; Gaba, L; Gonzalez Cortijo, L; Salutari, V; You, B; Chiang, S; O'Connor, M; Oplustil O'Connor, L; Meulendijks, D; Khatun, M; Ghiorghiu, D; Oaknin, A
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
2025 Oaknin, A; Monk, B; de Melo, A; Kim, H; Kim, Y; Lisyanskaya, A; Samouëlian, V; Lorusso, D; Damian, F; Chang, C; Gotovkin, E; Takahashi, S; Ramone, D; Maćkowiak-Matejczyk, B; Polastro, L; Alia, E; Colombo, N; Makarova, Y; Goh, J; Hasegawa, K; Mora, P; Pikiel, J; Srivastav, R; Rischin, D; Rubio, M; Perez, J; Yoo, S; Gao, B; Jamil, S; Seebach, F; Lowy, I; Mathias, M; Fury, M; Tewari, K
Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial
2025 Lorusso, D; Oaknin, A; Borges, G; Damian, F; Ottevanger, N; Van Gorp, T; Paiva, C; Kroep, J; Kim, Y; Kim, H; Lee, J; Denys, H; Lalisang, R; De Melo, A; Redondo, A; Reyners, A; Mora, P; Closset, C; Melief, C; Hooftman, L; Jamil, S; Boersma, L; Yoo, S; Seebach, F; Lowy, I; Fury, M; Mathias, M; Colombo, N
Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease
2025 Riva, C; Minetto, P; Chies, M; Vernarecci, C; Colombo, N; Rosellini, S; Parodi, A; Tedone, E; Carminati, E; Nurra, C; Puglisi, F; Frello, M; Maio, E; Ferro, B; Zecchetti, G; Fugazza, G; Nozza, P; Cea, M; Lemoli, R; Guolo, F
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
2025 Banerjee, S; Van Nieuwenhuysen, E; Aghajanian, C; D'Hondt, V; Monk, B; Clamp, A; Prendergast, E; Oaknin, A; Ring, K; Colombo, N; Holloway, R; Rodrigues, M; Chon, H; Gourley, C; Santin, A; Thaker, P; Gennigens, C; Newman, G; Salinas, E; Youssoufian, H; Moore, K; Lustgarten, S; O'Malley, D; Van Gorp, T; Grisham, R
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
2025 Matulonis, U; Herrstedt, J; Oza, A; Mahner, S; Redondo, A; Berton, D; Berek, J; Haslund, C; Marme, F; Gonzalez-Martin, A; Becourt, S; Tinker, A; Ledermann, J; Benigno, B; Lindahl, G; Colombo, N; Malinowska, I; Liu, W; Bains, M; Monk, B; Mirza, M
Erratum to ‘Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer’ [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101664] (International Journal of Gynecological Cancer (2025) 35(3), (S1048891X25001896), (10.1016/j.ijgc.2025.101664))
2025 Fumagalli, D; Jayraj, A; Olearo, E; Capasso, I; Hsu, H; Tzur, Y; Piedimonte, S; Jugeli, B; Santana, B; De Vitis, L; Caruso, G; Aletti, G; Colombo, N; Ramirez, P
ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025
2025 Concin, N; Matias-Guiu, X; Cibula, D; Colombo, N; Creutzberg, C; Ledermann, J; Mirza, M; Vergote, I; Abu-Rustum, N; Bosse, T; Chargari, C; Espenel, S; Fagotti, A; Fotopoulou, C; Gatius, S; Gonzalez-Martin, A; Lax, S; Levy, B; Lorusso, D; Macchia, G; Marth, C; Morice, P; Oaknin, A; Raspollini, M; Schwameis, R; Sehouli, J; Sturdza, A; Taylor, A; Westermann, A; Wimberger, P; Planchamp, F; Nout, R
External validation of the Annual Recurrence Risk Model (ARRM) for tailored surveillance strategy in patients with cervical cancer
2025 De Vitis, L; Schivardi, G; Gaeta, A; Caruso, G; Rosanu, M; Ribero, L; Fumagalli, D; Casarin, J; Betella, I; Bogani, G; Langstraat, C; Aletti, G; Colombo, N; Zanagnolo, V; Gandini, S; Multinu, F
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study
2025 Valenza, C; Nicolò, E; Mongillo, M; Trapani, D; Katrini, J; Boldrini, L; Boscolo Bielo, L; Castellano, G; Guidi, L; Pellizzari, G; Villa, J; Derio, S; Lapresa, M; Gigli, F; Parma, G; Omodeo Salè, E; Derenzini, E; Curigliano, G; Colombo, N
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer
2025 Grisham, R; Monk, B; Van Nieuwenhuysen, E; Moore, K; Fabbro, M; O'Malley, D; Oaknin, A; Thaker, P; Oza, A; Colombo, N; Gershenson, D; Aghajanian, C; Choi, C; Lee, Y; Mirza, M; Coleman, R; Cobb, L; Harter, P; Lustgarten, S; Youssoufian, H; Banerjee, S
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics
2025 Quesada, S; Penault-Llorca, F; Matias-Guiu, X; Banerjee, S; Barberis, M; Coleman, R; Colombo, N; Defazio, A; Mcneish, I; Nogueira-Rodrigues, A; Oaknin, A; Pignata, S; Pujade-Lauraine, É; Rouleau, É; Ryška, A; Van Der Merwe, N; Van Gorp, T; Vergote, I; Weichert, W; Wu, X; Ray-Coquard, I; Pujol, P
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer
2025 Bogani, G; Moore, K; Ray-Coquard, I; Lorusso, D; Matulonis, U; Ledermann, J; González-Martín, A; Kurtz, J; Pujade-Lauraine, E; Scambia, G; Caruso, G; Raspagliesi, F; Colombo, N; Monk, B
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial
2025 Poveda, A; Lheureux, S; Colombo, N; Cibula, D; Elstrand, M; Weberpals, J; Bjurberg, M; Oaknin, A; Sikorska, M; González-Martín, A; Madry, R; Rubio Pérez, M; Ledermann, J; Romero, I; Özgören, O; Barnicle, A; Marshall, H; Bashir, Z; Škof, E
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results
2025 Scambia, G; Villalobos Valencia, R; Colombo, N; Cibula, D; Leath, C; Bidzinski, M; Kim, J; Nam, J; Madry, R; Hernandez, C; Mora, P; Ryu, S; Ah-See, M; Lowe, E; Lukashchuk, N; Carter, D; Penson, R
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status: Clinical Studies
2025 Pignata, S; Oza, A; Hall, G; Pardo, B; Madry, R; Cibula, D; Klat, J; Montes, A; Glasspool, R; Colombo, N; Pete, I; Herrero Ibanez, A; Romeo, M; Ilieva, R; Timcheva, C; Di Maio, M; Bashir, Z; Taylor, R; Barnicle, A; Clamp, A
Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer
2025 Randall, L; Xiang, Y; Matsumoto, T; Giannarelli, D; Milla, D; Lopez, K; Acevedo, A; Vizkeleti, J; Salani, R; Nogueira-Rodrigues, A; Mejia, F; Korach, J; Akilli, H; Lee, J; Saevets, V; Samouelian, V; Sehouli, J; Tharavichikul, E; Sukhin, V; Colombo, N; Chang, C; Cueva, J; Lalondrelle, S; Petru, E; Szamreta, E; Nguyen, A; Yamada, K; Li, K; Pignata, S; Lorusso, D
Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): Overall Survival Results From a Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial
2025 Lorusso, D; Xiang, Y; Hasegawa, K; Scambia, G; Leiva, M; Ramos-Elias, P; Acevedo, A; Cvek, J; Randall, L; De Santana Gomes, A; Mejia, F; Helpman, L; Akilli, H; Lee, J; Saevets, V; Zagouri, F; Gilbert, L; Sehouli, J; Tharavichitkul, E; Lindemann, K; Colombo, N; Chang, C; Bednarikova, M; Zhu, H; Oaknin, A; Christiaens, M; Petru, E; Usami, E; Liu, P; Yamada, K; Toker, S; Keefe, S; Pignata, S; Duska, L
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study
2025 Lorusso, D; Colombo, N; Dubot, C; Cáceres, M; Hasegawa, K; Shapira-Frommer, R; Salman, P; Yañez, E; Gümüş, M; Olivera, M; Samouëlian, V; Castonguay, V; Arkhipov, A; Li, K; Toker, S; Tekin, C; Tewari, K; Monk, B
Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
2025 Kim, Y; Nishio, S; Kim, S; Hasegawa, K; Dubot, C; Valeria Cáceres, M; Tewari, K; Lorusso, D; Lee, J; Liou, W; Li, K; Tekin, C; Colombo, N; Monk, B